Pacira BioSciences Inc (NAS:PCRX)
$ 17.24 -0.46 (-2.6%) Market Cap: 796.03 Mil Enterprise Value: 986.64 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 71/100

Pacira Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 05:30PM GMT
Release Date Price: $42.5 (-1.82%)
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm Chris Schott from JPMorgan. And I'm very pleased today to be introducing Pacira. From the company, we have Dave Stack, the company's Chairman and CEO. We're going to have Dave make some opening comments, and we're going to go to a fireside-chat format from there. So Dave, welcome back to the conference and look forward to the presentation.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Great. Thank you, Chris, and thanks to JPMorgan for the opportunity to spend a few minutes with you folks today. Standard disclosures for a public company.

Just to confirm for folks that are not -- have not been close to Pacira, our mission and vision is to provide an opioid alternative to as many patients as possible. An interesting observation is that once our KOLs use our products that are available to eliminate osteoarthritic pain, we have a different conversation with the patients and they begin to request different approaches to enhance their

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot